DRMA enters the post-earnings session with a notable alignment: the CEO who spent $1 million buying shares in December is now watching the company he built beat Q1 estimates — and the short base that towered over the stock just six weeks ago has almost entirely unwound.
The insider story is the most striking feature of this setup. CEO Gerald Proehl spent roughly $1.25 million buying shares on December 23 at $2.04, acquiring a combined 612,745 shares across two tranches. CFO Kyri Van Hoose added a further 122,549 shares the same day at the same price, deploying around $250,000. The cluster was unmistakable: two of the most senior executives in a micro-cap biotech buying seven-figure positions in unison. The stock is now at $1.24, below those purchase prices — but the Q1 print just provided a tangible catalyst. Dermata reported Q1 EPS of -$0.48 against a -$0.53 estimate, a meaningful beat at a stage when preserving cash is the whole game.
The short interest picture tells the story of a dramatic repositioning. At the peak in late March, short interest briefly touched 30% of the free float — an extreme reading for a stock this small. Since then, shorts have retreated aggressively. By May 12, SI % FF had collapsed to just 2.9%, down from that March high and roughly flat on the week after a brief uptick. The 30-day change is -64%, confirming the bulk of the unwind happened through April. What remains is a residual short position, not an active bear campaign.
The borrow market still carries the scars of that earlier squeeze. Cost to borrow has eased sharply — from highs above 180% APR in early April to around 75% now, a 38% drop on the week — but 75% remains far above any normal borrowing cost for a biotech of this size. Borrow availability has loosened as shorts exited, with the lending pool less stressed than it was in March. The ORTEX short score sits at 57.9, up modestly on the week, reflecting a stock that is no longer under extreme short pressure but has not yet cleared to normal borrow conditions.
The analyst data is stale and should not be relied upon — the only on-record change is a Maxim Group target cut from August 2025, trimming the price target to $10 from $30, well before the company's recent share consolidation and restructuring. With the stock trading at $1.24, those figures are not directly comparable. The sole Nasdaq peer with meaningful correlation in the data is RNAZ, down 14% on the week and 4% in the session — a reminder that the small-cap biotech tape remains under pressure even as DRMA's own short dynamics improve.
The May 14 Q1 corporate update has now landed, with the EPS beat offering a modest operational positive. What the market will focus on next is whether the cash runway commentary in the 10-Q — filed alongside the results — is sufficient to shift the conversation away from survival and toward the pipeline. Proehl's December purchases sit at a loss, but the short base that made that position uncomfortable has largely dissolved.
See the live data behind this article on ORTEX.
Open DRMA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
